Study Details
Full Title
NRG-GY036, A Phase III Trial of One vs. Two Years of Maintenance Olaparib, with or without Bevacizumab, in Patients with BRCA1/2 Mutated or Homologous Recombination Deficient (HRD+) Ovarian Cancer Following Response to First Line Platinum-Based Chemotherapy (NCT#06580314)
Principal Investigator
Angeles
Secord
Protocol Number
PRO00117512
NCT ID
NCT06580314
Phase
III
Enrollment Status
Open to Enrollment